Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRISPR-Cas9 CXCL10 knockout refers to the targeted genetic deletion of the C-X-C motif chemokine ligand 10 (CXCL10) gene using the CRISPR-Cas9 gene-editing system. In the context of T-cell acute lymphoblastic leukemia (T-ALL) research, this modification is employed to investigate the role of the CXCR3/CXCL10 signaling axis in central nervous system (CNS) and meningeal infiltration. CXCL10 is primarily expressed by meningeal stromal cells in response to inflammatory cytokines (such as IFN-gamma and TNF) produced by infiltrating T-ALL cells. By knocking out CXCL10 in stromal cells or utilizing CXCL10-deficient mouse models, researchers have demonstrated a significant reduction in leukemic cell adhesion and migration to the meninges. This suggests that targeting the CXCL10 chemokine or its receptor, CXCR3, could be a viable therapeutic strategy to prevent or treat CNS involvement and relapse in T-ALL patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CRISPR-Cas9 CXCL10 knockout.